Where is CureVac located?

CureVac is located in Tubingen, Germany .

Who is the current CEO of CureVac?

Ingmar Hoerr is the current CEO of CureVac.

Which legal entities is CureVac associated with?

CureVac is associated with CureVac AG.

How many employees does CureVac have?

CureVac has 648 employees as of Dec 31, 2021.

When was the latest funding round of CureVac?

CureVac's latest funding round was on Sep 15, 2020.

What is the annual revenue of CureVac?

Annual revenue of CureVac is 鈧�3.12碍 as on Mar 31, 2020.

Is CureVac a Ophthalmology company?

The primary sectors of CureVac are Ophthalmology, Oncology, Immunotherapy, Infectious Diseases, Rare Diseases and Gene Therapy.

Where does CureVac rank among its competitors?

CureVac ranks 408 amongst 3510 active competitors.

Who are the top competitors of CureVac?

CureVac's top competitors are Moderna, Jazz Pharmaceuticals and BridgeBio.

CureVac - 2025 Company Profile, Funding & Competitors

Sectors and market segments that CureVac operate in

CureVac serves in the B2B space in the Life Sciences, market segments.The primary business model of CureVac are:

Company Details

Developer of mRNA-based therapeutics against cancer and infectious diseases. It has developed RNAntibody to enable the expression of functional antibodies and antibody-like proteins from mRNA. The lead product includes CV9104, an investigational therapeutic vaccine to treat prostate cancer. The vaccine is injected into the skin to stimulate the body's immune system to destroy prostate cancer cells. The company's other product includes CV8102 for cutaneous myeloma and CV9202 used to treat patients with non-small cell lung cancer.

Website
Social
Email ID: @curevac.com
Phone Number: +49 , +49

Key Metrics

Founded Year

2000

Location

Tubingen, Germany

Stage

Public

Total Funding

in 15 rounds

Latest Funding Round

Investors

& 14 more

Ranked

408^th among

Annual Revenue

as on Mar 31, 2020

Employee Count

as on Dec 31, 2021

Similar Companies

Moderna &

Exit Details

Public

Legal entities associated with CureVac

CureVac is associated with 1 legal entity given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
	Sep 16, 2015	$14.8M (as on Dec 31, 2018)	829	463

Get your free copy of CureVac's company profile

CureVac has raised a total funding of $975M over 15 rounds. Its first funding round was on 2003.

CureVac has 15 institutional investors including , Dievini and Qatar Investment Authority.

Here is the list of recent funding rounds of CureVac:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Sep 15, 2020	$299M	Grant (prize money)	-	-	-
Jul 21, 2020	$126M	Series F	-	-	Qatar Investment Authority
Jul 20, 2020	$171M	Series F	-	-	GSK

Access funding benchmarks and valuations. Sign up today!

View details of CureVac's funding rounds and investors

The founders of CureVac are , , and . is the CEO of CureVac.

CureVac's board has 3 active members. and are part of team and is independent board member.

View details of CureVac's Founder profiles and Board Members

CureVac's employee count trend

CureVac has 648 employees as of Dec 21. The total employee count is the same as what it was in Dec 20. Here is CureVac's employee count trend over the years:

Uncover CureVac's growth story! Sign up today!

Top competitors of CureVac include Moderna, Jazz Pharmaceuticals and BridgeBio. Here is the list of Top 10 competitors of CureVac, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Flagship Pioneering, Wellington听&补尘辫;听	86/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of therapeutics for cancer and neurological disorders	$265M	InterWest Partners, Investor Growth Capital听&补尘辫;听	85/100
3rd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Aisling Capital, Hercules Capital听&补尘辫;听	84/100
4th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	T. Rowe Price, Temasek听&补尘辫;听	83/100
5th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, HBM Partners听&补尘辫;听	82/100
6th	Recursion 2013, United States, Public	R&D based company focused on manufacturing of drugs for multiple therapeutic areas	$452M	HTIF, Menlo Ventures听&补尘辫;听	81/100
7th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Deerfield听&补尘辫;听	80/100
8th	Incyte 1991, Wilmington (United States), Public	Developer of small molecules for the treatment of different cancer and skin diseases	-	Tekla Capital Management, Ridgeback Capital Management听&补尘辫;听	78/100
9th	Revolution Medicines 2014, Redwood City (United States), Public	Developer of therapies for treating cancer	$181M	Vivo Capital, Deerfield听&补尘辫;听	78/100
10th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	New Enterprise Associates, Foresite Capital听&补尘辫;听	77/100
408th	2000, Tubingen (Germany), Public	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	European Investment Bank, 听&补尘辫;听	54/100